Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study

Authors not listed

Anne Fung MD · 2010

Abstract

In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are collecting groups of patients who either do not or only partially respond to anti-VEGF therapy. This study will evaluate the efficacy and safety of 2mg ranibizumab specifically for patients with fibrovascular PEDs that have not resolved following at least 6 consecutive injections of ranibizumab or bevacizumab over the previous 12 months. The investigators hypothesize that the 2mg dose will be able to completely eliminate the persistent PEDS in these patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-09 MST

Cite this

APA
Anonymous. (2010). High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study. <em>Anne Fung MD</em>. https://clinicaltrials.gov/study/NCT01189019
Vancouver
Anonymous. High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study. Anne Fung MD. 2010.
BibTeX
@misc{anon2010HighDo, title = {High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study}, author = {Anonymous}, journal = {Anne Fung MD}, year = {2010}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings